Inflammatory markers in SIRS, sepsis and septic shock
- PMID: 18336272
- DOI: 10.2174/092986708783769704
Inflammatory markers in SIRS, sepsis and septic shock
Abstract
Despite great advancement in the understanding of the pathophysiology and in the development of novel therapeutic approaches, mortality of sepsis still remains unacceptably high. Adequate laboratory diagnostics represents a major requirement for the improvement of this situation. For a better understanding of the immunological dysregulation in this disease, several markers are now available for routine diagnostics in the clinical laboratory. They include the cytokines interleukin (IL) -6, IL-8, procalcitonin and the LPS-binding protein (LBP). These novel markers will be compared to the conventional procedure of diagnosing inflammatory and infectious disease, such as measurements of C-reactive protein (CRP) as a major acute phase protein and differential blood counting. Important questions addressed in this review are the usefulness of these markers for early diagnosis, their role as prognostic markers and in the risk assessment of patients. Furthermore, we will discuss whether these parameters are to differentiate between systemic inflammatory response syndrome (SIRS) and sepsis at its different degrees. In the case of an infectious nature of the disease, it is important to differentiate between viral or bacterial origin and to monitor the responsiveness of antibiotic therapies. The literature was analysed with focus on the evidence for diagnostic and analytical performance. For this purpose international definition and staging criteria were used in context of criteria for assay performance including sensitivity, specificity, negative and positive predictive values, ROC analysis and other analytical criteria.
Similar articles
-
Procalcitonin for early diagnosis and differentiation of SIRS, sepsis, severe sepsis, and septic shock.Intensive Care Med. 2000 Mar;26 Suppl 2:S148-52. doi: 10.1007/BF02900728. Intensive Care Med. 2000. PMID: 18470710
-
[Comparison of procalcitonin, interleukin-6 and C-reactive protein in the differential diagnosis of patients with sepsis syndrome in intensive care units].Vnitr Lek. 2003 Jul;49(7):541-7. Vnitr Lek. 2003. PMID: 12931436 Czech.
-
[Procalcitonin for the differential diagnosis of infectious and non-infectious systemic inflammatory response syndrome after cardiac operation].Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2014 Jul;26(7):478-9. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2014. PMID: 25163104 Chinese.
-
The efficacy of procalcitonin as a biomarker in the management of sepsis: slaying dragons or tilting at windmills?Surg Infect (Larchmt). 2013 Dec;14(6):489-511. doi: 10.1089/sur.2012.028. Epub 2013 Nov 25. Surg Infect (Larchmt). 2013. PMID: 24274059 Review.
-
[Procalcitonin as a marker of the systemic inflammatory response to infection].Medicina (Kaunas). 2004;40(7):696-701. Medicina (Kaunas). 2004. PMID: 15252237 Review. Lithuanian.
Cited by
-
Modulation of redox-sensitive transcription factors with polyphenols as pathogenetically grounded approach in therapy of systemic inflammatory response.Heliyon. 2023 Apr 16;9(5):e15551. doi: 10.1016/j.heliyon.2023.e15551. eCollection 2023 May. Heliyon. 2023. PMID: 37180884 Free PMC article. Review.
-
The interaction of MD-2 with small molecules in huanglian jiedu decoction play a critical role in the treatment of sepsis.Front Pharmacol. 2022 Sep 9;13:947095. doi: 10.3389/fphar.2022.947095. eCollection 2022. Front Pharmacol. 2022. PMID: 36160407 Free PMC article.
-
Translational and Clinical Significance of DAMPs, PAMPs, and PRRs in Trauma-induced Inflammation.Arch Clin Biomed Res. 2022;6(5):673-685. doi: 10.26502/acbr.50170279. Epub 2022 Aug 26. Arch Clin Biomed Res. 2022. PMID: 36147548 Free PMC article.
-
Retracted Article: A high-throughput metabolomics strategy for discovering the influence of differential metabolites and metabolic pathways of huaxian capsules on sepsis-associated Qi deficiency and blood stasis syndrome.RSC Adv. 2019 Sep 30;9(53):30868-30878. doi: 10.1039/c9ra06679a. eCollection 2019 Sep 26. RSC Adv. 2019. PMID: 35529408 Free PMC article. Retracted.
-
Tumor Necrosis Factor-α Mediates Lung Injury in the Early Phase of Endotoxemia.Pharmaceuticals (Basel). 2022 Feb 24;15(3):287. doi: 10.3390/ph15030287. Pharmaceuticals (Basel). 2022. PMID: 35337084 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
